Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)

• Company Description    Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.88 Daily Weekly Monthly 20 Day Moving Average: 2,864,404 shares Shares Outstanding: 17.42 (millions) Market Capitalization: $15.26 (millions) Beta: 3.68 52 Week High: $4.49 52 Week Low: $0.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.79% 6.88% 12 Week -21.79% -28.95% Year To Date -68.26% -71.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1776 YORKTOWN SUITE 550 - Houston,TX 77056 USA ph: 832-260-0222 fax: - nxl@crescendo-ir.com http://www.nexalin.com

• General Corporate Information    Officers Mark White - Chief Executive Officer and Chief Financial Office Carolyn Shelton - Senior Vice President of Quality; Clinical and Reg Alan Kazden - Director Ben Hu - Director Leslie Bernhard - Director Peer Information Nexalin Technology, Inc. (EVOL) Nexalin Technology, Inc. (RAMP) Nexalin Technology, Inc. (LGTY) Nexalin Technology, Inc. (ALOT) Nexalin Technology, Inc. (CXT) Nexalin Technology, Inc. (TGHI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Technology Services Sector: Business Services CUSIP: 65345B201 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/14/25 Share - Related Items Shares Outstanding: 17.42 Most Recent Split Date: (:1) Beta: 3.68 Market Capitalization: $15.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.52 Price/Cash Flow: - Price / Sales: 87.19 EPS Growth vs. Year Ago Period: 41.18% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 162.96% vs. Previous Quarter: 73.17% ROE 06/30/25 - -209.20 03/31/25 - -277.92 12/31/24 - -247.11 ROA 06/30/25 - -186.87 03/31/25 - -245.37 12/31/24 - -219.24 Current Ratio 06/30/25 - 10.43 03/31/25 - 4.56 12/31/24 - 7.24 Quick Ratio 06/30/25 - 10.14 03/31/25 - 4.25 12/31/24 - 6.92 Operating Margin 06/30/25 - -5,057.14 03/31/25 - -6,529.01 12/31/24 - -4,500.59 Net Margin 06/30/25 - -5,057.14 03/31/25 - -6,529.77 12/31/24 - -4,501.18 Pre-Tax Margin 06/30/25 - -5,057.14 03/31/25 - -6,528.25 12/31/24 - -4,511.59 Book Value 06/30/25 - 0.35 03/31/25 - 0.17 12/31/24 - 0.28 Inventory Turnover 06/30/25 - 0.33 03/31/25 - 0.25 12/31/24 - 0.23 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©